Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
23.05.23
/
50%
€21.20
Target price
23.05.24
€23.22
Performance (%)
-17.45%
Price
25.04.24
€16.70
Summary
This prediction is currently active. The prediction for Myriad Genetics disappoints with a performance of -17.45%. This prediction currently runs until 23.05.24. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Myriad Genetics | 0.578% | 0.578% |
| iShares Core DAX® | 1.051% | -1.833% |
| iShares Nasdaq 100 | -0.547% | -3.738% |
| iShares Nikkei 225® | -1.778% | -8.115% |
| iShares S&P 500 | 0.002% | -2.226% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "sell" rating to a "buy" rating. They now have a $25.00 price target on the stock, up previously from $18.00.
Ratings data for MYGN provided by MarketBeat